Alkermes Plc
NASDAQ:ALKS
Alkermes Plc
NASDAQ:ALKS
Price:
29.37
USD
3.42%
Market Closed
Market Cap:
$4.9B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Alkermes Plc
NASDAQ:ALKS
|
IE |
|
Camellia PLC
LSE:CAM
|
UK |
|
Karooooo Ltd
NASDAQ:KARO
|
SG |
|
Tohoku Electric Power Co Inc
TSE:9506
|
JP |
|
Vault Minerals Ltd
ASX:VAU
|
AU |
|
Bukaka Teknik Utama Tbk PT
IDX:BUKK
|
ID |
|
B
|
Blue Zones Holdings Co Ltd
TSE:417A
|
JP |
|
Panca Anugrah Wisesa Tbk PT
IDX:MGLV
|
ID |
|
A
|
Aalberts NV
AEX:AALB
|
NL |
|
Kunwu Jiuding Investment Holdings Co Ltd
SSE:600053
|
CN |
|
Foley Wines Ltd
NZX:FWL
|
NZ |
|
J
|
Jacobs Solutions Inc
F:Z0Y
|
US |
|
Formosa Plastics Corp
TWSE:1301
|
TW |
|
Z
|
Zuger Kantonalbank
SIX:ZUGER
|
CH |
|
Shaftesbury Capital PLC
LSE:SHC
|
UK |
|
Kyushu Electric Power Co Inc
TSE:9508
|
JP |
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
KR |
|
Thunderbird Entertainment Group Inc
XTSX:TBRD
|
CA |
Relative Value
The Relative Value of one
ALKS
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 29.37 USD,
Alkermes Plc
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ALKS Relative Value
HIDDEN
Multiples Across Competitors
ALKS Competitors Multiples
Alkermes Plc Competitors
Alkermes Plc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IE |
|
Alkermes Plc
NASDAQ:ALKS
|
4.9B USD | 3.3 | 20.1 | 15.4 | 17 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
366.3B USD | 6 | 87.5 | 14.5 | 20.2 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
355.9B USD | 109.6 | -1 710.6 | 15 890.6 | -1 794.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
190.8B USD | 5.2 | 24.7 | 14.3 | 14.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
171.6B USD | 5.8 | 20.2 | 12.6 | 15.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.6B USD | 9.6 | 29.2 | 22 | 23 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD | 5.5 | 17.6 | 13 | 14.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68B AUD | 3.2 | 35.2 | 11.6 | 14.6 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
